Applying a historical science as a practical science: big data, evolution, medicine, and public health by Townsend, Jeffrey
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Day of Data Day of Data 2015
Sep 18th, 4:15 PM - 5:15 PM
Applying a historical science as a practical science:
big data, evolution, medicine, and public health
Jeffrey Townsend
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/dayofdata
This Event is brought to you for free and open access by EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for
inclusion in Yale Day of Data by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information,
please contact elischolar@yale.edu.
Jeffrey Townsend, "Applying a historical science as a practical science: big data, evolution, medicine, and public health" (September 18,
2015). Yale Day of Data. Paper 1.
http://elischolar.library.yale.edu/dayofdata/2015/Schedule/1
Applying a historical science as a practical science: 
big data, evolution, medicine, and public health 
Jeffrey P. Townsend, Ph.D. 
Associate Professor of Biostatistics and Ecology & Evolutionary Biology 
Director of Bioinformatics, Yale Center for Analytical Sciences 
Yale University
Evolutionary biology is usually 
considered a historical science
Ernst Haeckel (1866)
Increases in sequencing data have provided 
enormous illumination regarding the disciplinary 
mission of illuminating the deep history of life
David Hillis (2003)
Text
The production of increasing amounts 
of sequence data has provided 
increasing resolution
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Text
Diverse types of information on 
evolutionary history follow a 
characteristic function 
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Illumination of the deep history of life 
has mostly disciplinary outcomes
David Hillis (2003)
Text
More data is especially helpful not only 
for deep evolutionary questions, but 
also extremely recent ones
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Two examples of interdisciplinary collaboration 
using the techniques of evolutionary biology 
facilitated by next-generation sequencing data
a collaboration with 
modelers in the School 
of Public Health, where 
only now are sequencing 
and analysis are getting 
rapid enough and 
sophisticated enough to 
provide revealing 
information about 
ongoing epidemics
Two examples of interdisciplinary collaboration 
using the techniques of evolutionary biology 
facilitated by next-generation sequencing data
with pathologists, 
geneticists, and 
pharmacologists in the 
School of Medicine and 
an industrial parter, we 
sequenced, processed, 
stored, managed, and 
shared results from a 
massive tumor 
sequencing program
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Genomic surveillance data was quickly released 
for the 2014 West African Ebola outbreak
Text
Epidemiological and viral genomic 
sequence analysis of the 2014 Ebola 
outbreak reveals clustered transmission
Text
Our analysis revealed something of 
key importance that had no other 
means for evaluation: underreporting
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Our analysis revealed something of 
key importance that had no other 
means for evaluation: underreporting
Text
More data is especially helpful not only 
for deep evolutionary questions, but 
also extremely recent ones
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Two examples of interdisciplinary collaboration 
using the techniques of evolutionary biology 
facilitated by next-generation sequencing data
with pathologists, 
geneticists, and 
pharmacologists in the 
School of Medicine and 
an industrial parter, we 
sequenced, processed, 
stored, managed, and 
shared results from a 
massive tumor 
sequencing program
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Melanoma (complete) 354 82712
Metastatic colon cancer 177 16444
Autopsy samples 171 40821
Ovarian cancer 161 10715
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carcinoma 108 21461
Largest projects by sample count
Nearly 400k somatic 
mutations have been 
uploaded to 26 Yale-
Gilead projects. 
• 1668 matched tumors 
• 216 unmatched tumors 
• additional 12 TCGA datasets  
• and 2 projects with raw paths only
https://cancerdb.eeb.yale.edu/progress.jsp
Text
Significantly altered pathways can 
clarify “common pathway” origins of 
cancers.
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• Identifies pathways with a greater 
mutation burden than would be 
expected by chance, given pathway 
size. 
• Users can browse plots for each 
pathway to aid identification of 
important: 
• matrix plots show all pathway 
mutations and can indicate 
exclusivity and co-occurrence 
• ‘target’ plots show genes scaled 
according to mutation frequencies
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Significantly altered pathways can clarify “common pathway” origins of cancers.
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• ‘target’ plots show genes scaled according to mutation frequencies
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More data is especially helpful not only 
for deep evolutionary questions, but 
also extremely recent ones
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These evolutionary 
methodologies 
can be applied to 
cancer
Tumor tissues:
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Text
Tissue cores were extracted from 
normal tissue, primary tumors, and 
metastases
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A phylogenetic analysis can address 
questions about the timing and 
relationships of metastases
• Are there single or multiple genetic origins of 
metastases within the primary tumor? 
• How early do metastases genetically diverge 
from primary tumors? 
• What is the chronology of cancerous tissue 
origination? 
• Do driver mutations occur early or late in 
cancer?
A linear model for all cancer is not 
supported. Some genetic, epigenetic, or 
physiological disposition toward metastasis is.
• Of 16 cancer phylogenies featuring a well-supported 
topological position of the primary tumor, 6 (38%) 
exhibited a most likely topology in which metastatic 
tumor lineages were not monophyletic and the 
primary tumor was not the outgroup to all metastases
• Integration over Bayesian posteriors for all 32 
phylogenies yielded 45% (CI 31%–56%)
• This value, significantly higher than the random 
expectation of 21%, demonstrates that heritable 
genetic, epigenetic, or other lineage-specific events can 
contribute a proclivity within lineages toward 
metastasis of the primary tumor. However, the lineage-
specific effect is not so strong as to universally lead to 
monophyletic metastases as predicted by the linear 
model (P < 10−11)
Genetic divergence of metastatic lineages 
from primary tumors can occur early
in tumor evolution
TimeNormal Death
Probability density
• In the cancer molecular evolutionary trees for 11 
out of 40 subjects, the shared ancestral lineage of all 
tumors was shorter than the subsequent branch 
lengths leading to a metastatic tissue sampled at 
autopsy.
• The first genetic divergence of metastasis usually 
predated diagnosis.
• We inferred cancer chronograms by applying a 
relaxed clock calibrated with the timings of diagnosis, 
biopsy, surgical resection, and autopsy, and 
parameterized by cell division times of primary tumor 
cells
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“Known driver mutations” could be mapped to 
 the tumorigenesis lineage prior to all tumor tissue, or to 
the premetastatic lineage prior to all metastatic tissue.
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Text
Integration over uncertainty in timing yielded 
probability distributions across patients for 
timing of driver gene mutation
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Cancer treatment by targeted drug 
therapies is growing increasingly complex: 
an example of a patient with melanoma
Gene Mutation Drug Antineoplastic? Mutation	  Freq.	  	  (%)
CUBN S1231N Hydroxocobalamin No 9.27
AASS E537D NADH,	  L-­‐Glutamic	  acid No 4.44
PTEN I303S 1372540-­‐25-­‐4 Yes 4.03
MAN2A1 G1033D Ghavamiol,	  swainsonine No 3.63TEP1 A1974T GRN163L No	   3.23
PAPSS1 R445W ADP,	  Glycerol No 2.82
NRP2 R421W Daunorubicin No 2.02
MAP2K2 C125S Trametinib,	  Mek162,	  Selumetinib Yes 2.02ARAF G322S LGX818,	  Sorafenib,	  Regorafenib,	  XL281 Yes 1.61ANXA11 P83S Bevacizumab No 1.21
CASK P239S Formic	  acid No 1.21
CXCL12 M1T Tinzaparin	  (binder) No 0.81
G6PD D194E Doxorubicin,	  Aspirin,	  Chloroquine,	  Artesunate,	   No 0.40
Of	  	  104	  genes	  mutated,	  13	  have	  known	  drugs	  that	  target	  them,	  with	  3	  of	  these	  being	  anti-­‐neoplastic.	  
Table	  5:	  Patient's	  Mutated	  Genes	  with	  Known	  Drug	  Targets	  
 4     k   t   , ith 3 of these  i- e la tic. 
Text
Analyses will increasingly have to to 
consider the fitness landscape of 
cancer mutations across multiple genes
Text
More data is especially helpful not only 
for deep evolutionary questions, but 
also extremely recent ones
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Two examples of interdisciplinary collaboration 
using the techniques of evolutionary biology 
facilitated by next-generation sequencing data
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““It all boils down to this: that all life is 
interrelated. We are all caught in an 
inescapable network of mutuality, tied into a 
single garment of destiny. Whatever affects one 
destiny, affects all indirectly.”
–Martin Luther King, Jr.
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